Cardiovascular Risk Assessment in Patients With Severe Psoriasis Treated With Biologic Agents
Psoriasis is a common inflammatory disease of the skin and joints with a prevalence of 1-3% in the caucasian population of Northern Europe and the US. Similarly to other inflammatory diseases there is now substantial and accumulating evidence that psoriasis has a systemic inflammatory component.
It is known that patients suffering from psoriasis have increased prevalence of traditional cardiovascular risk factors, such as hypertension, dyslipidaemia, obesity, tobacco use and diabetes mellitus. This would logically explain an increased rate of cardiovascular events, but even when adjusting for theses risk factors, psoriasis carry an independent risk for developing cardiovascular disease.
Recent large epidemiological studies have shown a strong correlation between psoriasis and myocardial infarction.
In conclusion, convincing and increasing evidence is supporting that psoriasis induce accelerated atherosclerosis and hence cardiovascular disease and mortality. In particular, this is seen in young patients with early disease onset.
Psoriasis is believed to be driven by cytokines produced by Th1 and Th17 lymphocytes. A number of these cytokines are suggested to be atherogenic. In contrast, another chronic inflammatory disease, atopic dermatitis, is predominantly driven by Th2 lymphocyte derived cytokines, some of which may inhibit atherosclerotic processes. It is therefore, of interest to compare the presence of cardiovascular disease in these two inflammatory skin diseases.
Hypothesis: That the risk of developing cardiovascular disease and especially coronary artery disease is increased in psoriasis patients and that this process can be influenced by treatment of psoriasis with biological treatment.
|Study Design:||Observational Model: Case Control
Time Perspective: Prospective
|Official Title:||Cardiovascular Risk Assessment in Patients With Severe Psoriasis Treated With Biologic Agents|
- Coronary calcium score [ Time Frame: 0 and 12 months ] [ Designated as safety issue: No ]both calcified and soft plaques will be evaluated
- Cardiovascular risk markers [ Time Frame: 0, 3 and 12 months ] [ Designated as safety issue: No ]hs-crp, homocystein, SBHG, apolipoprotein B, MBL, PAPP-A.
- interleukines in blood [ Time Frame: 0, 3 and 12 months ] [ Designated as safety issue: No ]selected cytokines (amongst: TNFα, IL-1, IL-6, IL-8, IL-10, IL-12, IL-13, IL-15, IL17A, IL-19, IL-20, IL-23, IFN, ICAM-1, E-selectin)
- traditional cardiovascular risk factors [ Time Frame: 0, 3 and 12 months ] [ Designated as safety issue: No ]monitoring of blood cholesterol levels and blood glucose.
Biospecimen Retention: Samples With DNA
blood and skin samples.
|Study Start Date:||March 2011|
|Estimated Study Completion Date:||July 2015|
|Estimated Primary Completion Date:||July 2014 (Final data collection date for primary outcome measure)|
Psoriasis topical treatment
Psoriasis topical treatment. No systemic drugs.
Psoriasis biological treatment
Psoriasis biological treatment. Anti-Tnf and anti-il12/23.
Drug: biological treatment
patients treated with anti-psoriatic biological agents
Severe atopic dermatitis
Severe atopic dermatitis
No intervention. No inflammatory skin disease.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01356758
|Contact: Kasper F Hjuler, M.D.||+email@example.com|
|Contact: M Larsen, Secr.||firstname.lastname@example.org|
|Dep. of Dermatology||Recruiting|
|Aarhus C, Denmark, 8000|
|Principal Investigator: Kasper F Hjuler, M.D.|
|Principal Investigator:||Kasper F Hjuler, M.D.||Aarhus University Hospital|